Precigen
{{Infobox company
| name = Precigen, Inc.
| logo = The Precigen company logo from 2020.jpg
| type =
| industry = Biotechnology
| fate =
| traded_as = {{NASDAQ|PGEN}}
Russell 2000 Component
| predecessor =
| successor =
| founded = {{Start date and age|1998|05|21}}
| founder =
| defunct =
| hq_location_city = Germantown, Maryland
| hq_location_country = US
| area_served =
| key_people =
| products =
| owner =
| num_employees = 600
| revenue ={{Increase}} $91 million (2019){{Cite web|url=https://www.macrotrends.net/stocks/charts/PGEN/precigen/revenue|title=Precigen Revenue 2012-2021 | PGEN}}
| num_employees_year =
| parent =
| website = {{URL|precigen.com}}
}}
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.{{cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=22365961 |title=Intrexon Corporation: Private Company Information |publisher=Bloomberg |access-date=2017-06-26}}{{cite web|url=https://www.reuters.com/finance/stocks/companyProfile?symbol=XON |title=Intrexon Corp (XON) Company Profile |publisher=Reuters.com |access-date=2017-06-26}}{{dead link|date=July 2021|bot=medic}}{{cbignore|bot=medic}} With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.{{Cite news|url=http://investors.dna.com/FAQ|title=FAQ {{!}} Intrexon|work=Intrexon InvestorRoom|access-date=2018-03-28|language=en}}
History
In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million.{{cite news|url=https://www.reuters.com/article/us-agriculture-tech-investment-idUSKCN0RF2FU20150915|title=Market turbulence or not, North American investors plow into farm tech|last=Nickel|first=Rod|date=15 September 2015|newspaper=Reuters|access-date=9 October 2015}} In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.{{cite web |url=https://clinicaltrials.gov/ct2/show/NCT03927261|title=PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS|publisher=FDA|access-date=6 April 2020}}{{cite news |last=Gilgore|first=Sara|date=6 January 2020|title=Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.|url=https://www.bizjournals.com/washington/news/2020/01/06/intrexon-will-take-the-name-of-its-subsidiary-that.html|work=American City Business Journals|access-date=6 April 2020}} In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.{{cite web |url=https://precigen.com/intrexon/|title=INTREXON CORPORATION IS NOW PRECIGEN, INC|publisher=Precigen|access-date=6 April 2020}}{{cite news |last=Helmstetter|first=Michael|date=30 March 2020|title=The Promise And Fear Of Gene Editing|url=https://www.forbes.com/sites/michaelhelmstetter/2020/03/30/the-promise-and-fear-of-gene-editing/#741a8c042b8e|work=Forbes|access-date=6 April 2020}} With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.
See also
References
{{Reflist}}
External links
{{Official website|https://precigen.com/}}
{{Authority control}}
Category:American companies established in 1998